AB062. P-33. Efficacy and safety of varlitinib, a reversible pan-HER tyrosine kinase inhibitor, in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase 1 studies

BACKGROUND: Varlitinib is a nanomolar inhibitor of EGFR, HER2, and HER4 and has shown potent anti-tumor activity as monotherapy in preclinical BTC models. During phase (Ph) 1 development, significant tumor shrinkage was observed in biliary tract cancer (BTC) patients (pts). Tissue microarray analysi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Hepatobiliary Surg Nutr
Glavni autori: Tan, Aaron C., Oh, Do-Youn, Chao, Yee, Hsieh, Chih-Yi, Chang, Wei-Ling, Isanto, Fenny, Chen, Ying-Chen, McHale, Mark, Lindmark, Bertil, Ng, Matthew C. H.
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2019
Teme:
Poster Abstracts
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6421168/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/hbsn.2019.AB062
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items